### UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549

#### FORM 8-K

### CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): December 14, 2023

# **BIO-PATH HOLDINGS, INC.**

(Exact name of registrant as specified in its charter)

Delaware	001-36333	87-0652870
(State or other jurisdiction of incorporation)	(Commission File Numb	ber) (IRS Employer Identification No.)
4710 Bellaire Boulevard, Suite	e 210, Bellaire, Texas	77401
(Address of principal ex	ecutive offices)	(Zip Code)
(Registra	(832) 742-1357 ant's Telephone Number, Includ	ling Area Code)
(Former Name	e or Former Address, if Change	ed Since Last Report)
Check the appropriate box below if the F registrant under any of the following prov		imultaneously satisfy the filing obligation of the
	14a-12 under the Exchange Act s pursuant to Rule 14d-2(b) und	
Securities registered pursuant to Section 1	2(b) of the Act:	
Title of each class  Common Stock, par value \$0.001 per sh	are Trading Symbol BPTH	Name of each exchange on which registered The Nasdaq Capital Market
		ompany as defined in Rule 405 of the Securities change Act of 1934 (§240.12b-2 of this chapter).
		Emerging growth company $\square$
		nt has elected not to use the extended transition adards provided pursuant to Section 13(a) of the

### Item 5.07 Submission of Matters to a Vote of Security Holders.

On December 14, 2023, Bio-Path Holdings, Inc. (the "Company") called to order its 2023 annual meeting (the "Annual Meeting") of stockholders of the Company. At the Annual Meeting, the Company's stockholders: (i) elected the five persons listed below under Proposal 1 to serve as directors of the Company, to hold office until the Company's next annual meeting of stockholders or until their respective successors have been duly elected and qualified; and (ii) ratified and approved the appointment of Ernst & Young, LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending December 31, 2023. The following describes the results of the voting at the Annual Meeting:

<u>Proposal 1</u>: For the election of directors of the Company, to hold office until the Company's next annual meeting of stockholders or until their respective successors have been duly elected and qualified:

Name of Nominee	Shares Voted "For"	Shares Voted "Against"	Shares Withheld	Shares Abstained	Broker Non- Votes
Peter H. Nielsen	1,695,684		264,310		4,018,949
Heath W. Cleaver	1,697,485		262,509		4,018,949
Paul D. Aubert	1,711,337		248,657		4,018,949
Aline Sherwood	1,698,004		261,990		4,018,949
Douglas P. Morris	1,723,327		236,667		4,018,949

<u>Proposal 2</u>: For the ratification and approval of the appointment of Ernst & Young, LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2023:

Shares Voted "For"	Shares Voted	Shares	Shares	Broker Non-
	"Against"	Withheld	Abstained	Votes
5,881,335	78,314		19,294	

### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this Current Report to be signed on its behalf by the undersigned hereunto duly authorized.

## **BIO-PATH HOLDINGS, INC.**

Dated: December 15, 2023 By:/s/ Peter H. Nielsen

Peter H. Nielsen President and Chief Executive Officer